|Bid||187.110 x 400|
|Ask||187.130 x 200|
|Day's Range||186.870 - 188.960|
|52 Week Range||133.640 - 191.100|
|PE Ratio (TTM)||17.07|
|Dividend & Yield||4.60 (2.47%)|
|1y Target Est||N/A|
Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.
Amgen Inc NASDAQ/NGS:AMGN
A "biosimilar" version of the cancer drug Avastin — Genentech Inc.'s best-selling oncology treatment — was approved Thursday by the Food and Drug Administration, potentially crimping the $6 billion franchise of the South San Francisco-based drug maker's Swiss parent. The drug, which Amgen Inc. (AMGN) and partner Allergan plc (AGN) will sell as Mvasi, also is known by the scientific name bevacizumab. The drug regulator's approval allows it to be used to treat metastatic colorectal cancer and types of lung, kidney, cervical and brain cancers.